Stay updated on APG-115 + Pembrolizumab in Metastatic Melanomas Clinical Trial
Sign up to get notified when there's something new on the APG-115 + Pembrolizumab in Metastatic Melanomas Clinical Trial page.

Latest updates to the APG-115 + Pembrolizumab in Metastatic Melanomas Clinical Trial page
- Check7 days agoNo Change Detected
- Check14 days agoChange DetectedThe page shows a minor version update, Revision: v3.3.2, replacing v3.3.1, with no changes to study details, eligibility, or results. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check21 days agoChange DetectedRevision metadata was updated: v3.3.1 added and v3.2.0 removed; no core study content, eligibility criteria, or outcomes appear to have changed. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check29 days agoChange DetectedThe site-wide notice about government funding status was removed. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.3%

- Check43 days agoChange DetectedNo additions or deletions were detected on the page based on the provided context.SummaryDifference0.4%

- Check71 days agoChange DetectedSummary: The page now displays an updated operating-status notice for NIH Clinical Center and a new version tag (v3.2.0), replacing the old v3.1.0.SummaryDifference3%

- Check79 days agoChange DetectedUpdate: page version bumped from v3.0.2 to v3.1.0; no other substantive content changes shown.SummaryDifference0.2%

Stay in the know with updates to APG-115 + Pembrolizumab in Metastatic Melanomas Clinical Trial
Enter your email address, and we'll notify you when there's something new on the APG-115 + Pembrolizumab in Metastatic Melanomas Clinical Trial page.